The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administration of a Novel Anti-NGF Monoclonal Antibody (AK115) in Healthy Participants: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Trial.
Saved in:
| Title: | The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administration of a Novel Anti-NGF Monoclonal Antibody (AK115) in Healthy Participants: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Trial. |
|---|---|
| Authors: | Zhang J; Research Center of Clinical Pharmacology, the First Affiliated Hospital of Yunnan University of Chinese Medicine, Yunnan, People's Republic of China.; Research Center for Early Clinical Trials of Drugs (Vaccines), the Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, People's Republic of China., Fan YX; Research Center of Clinical Pharmacology, the First Affiliated Hospital of Yunnan University of Chinese Medicine, Yunnan, People's Republic of China., Huang Y; Research Center of Clinical Pharmacology, the First Affiliated Hospital of Yunnan University of Chinese Medicine, Yunnan, People's Republic of China., Guan R; Research Center of Clinical Pharmacology, the First Affiliated Hospital of Yunnan University of Chinese Medicine, Yunnan, People's Republic of China., Li R; Research Center of Clinical Pharmacology, the First Affiliated Hospital of Yunnan University of Chinese Medicine, Yunnan, People's Republic of China., Long S; Research Center of Clinical Pharmacology, the First Affiliated Hospital of Yunnan University of Chinese Medicine, Yunnan, People's Republic of China., Yang M; Research Center of Clinical Pharmacology, the First Affiliated Hospital of Yunnan University of Chinese Medicine, Yunnan, People's Republic of China., Yu B; Akeso Biopharma, Inc, Zhongshan, People's Republic of China., Wang GQ; Akeso Biopharma, Inc, Zhongshan, People's Republic of China., Chen P; Akeso Biopharma, Inc, Zhongshan, People's Republic of China., Gong X; Akeso Biopharma, Inc, Zhongshan, People's Republic of China., Li B; Akeso Biopharma, Inc, Zhongshan, People's Republic of China., Xia M; Akeso Biopharma, Inc, Zhongshan, People's Republic of China., He J; Research Center of Clinical Pharmacology, the First Affiliated Hospital of Yunnan University of Chinese Medicine, Yunnan, People's Republic of China. |
| Source: | Drug design, development and therapy [Drug Des Devel Ther] 2025 Apr 24; Vol. 19, pp. 3225-3235. Date of Electronic Publication: 2025 Apr 24 (Print Publication: 2025). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I |
| Journal Info: | Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1177-8881 |
|---|---|
| DOI: | 10.2147/DDDT.S500902 |
